The re-evaluation system of western medicines at home and abroad has been preliminarily formed. It is clear that the post-marketing re-evaluation of drugs must be based on the latest research data of the drugs, the purpose of the re-evaluation should be determined according to the needs of different subjects, and appropriate methods should be selected to carry out the re-evaluation research. Although the post-marketing re-evaluation research of traditional Chinese medicine has made some progress, there are still many problems in this field due to the differences in the theoretical systems of Chinese and Western medicine and the deficiencies of pre-marketing research. This article summarized the status of post-marketing clinical re-evaluation research of traditional Chinese medicine, analyzed the problems, and proposed key technology improvement methods for the post-marketing clinical re-evaluation research of Chinese patent medicines and Chinese herbal medicine pieces. It is hoped that a high-level comprehensive post-marketing clinical re-evaluation system for traditional Chinese medicines based on real world study would be formed based on multi-level, multi-source, multi-method research data and results, which will provide a basis for the rational use of traditional Chinese medicine and the formulation of national drug policies.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |